Advertisement

Hormones

, Volume 16, Issue 3, pp 291–296 | Cite as

Pegvisomant-primed growth hormone (GH) stimulation test is useful in identifying true GH deficient children

  • Giorgio Radetti
  • Heba H. Elsedfy
  • Randa Khalaf
  • Cristina Meazza
  • Sara Pagani
  • Mohamed El Kholy
  • Riccardo Albertini
  • Anna Maria De Stefano
  • Antonella Navarra
  • Annalisa De Silvestri
  • Mauro Bozzola
Research paper

Abstract

OBJECTIVE: Provocative stimulation tests for growth hormone (GH) assessment have poor reproducibility and can often elicit false positive results in normal children. The aim of our study was to confirm the capability of pegvisomant as an enhancer of GH secretion in unmasking false-positive results in short children (height <−2.0 standard deviation score, SDS) undergoing GH testing. DESIGN: A prospective study was conducted between March and August 2016. Twenty short children (10 males and 10 females), aged 4.6–13.4 years, previously diagnosed as GH deficient (GHD) were included in the study. All subjects received 1 mg/kg of pegvisomant subcutaneously; three days later an insulin tolerance test (ITT) was performed. Insulin-like growth factor-I (IGF-I) was evaluated before and three days after pegvisomant administration. RESULTS: After pegvisomant priming and the ITT stimulation test, 12 out of the 20 children initially classified as GHD showed a GH peak of more than 10 ng/ml and were thus reclassified as short normal. Furthermore, a significant reduction of IGF-I was observed in the GHD group (pre IGF-I: median (IQR) 144.0 (109–248) ng/ml, post IGF-I: 98 (49–165) ng/ml; p<0.001) after pegvisomant administration. CONCLUSIONS: Pegvisomant priming before GH stimulation tests can be used to improve the reliability of the diagnostic work-up in GH deficiency.

Key words

GH GHD GH stimulation tests Pegvisomant 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tassoni P, Cacciari E, Cau M, et al, 1990 Variability of growth hormone response to pharmacological and sleep tests performed twice in short children. J Clinical Endocrinol Metab 71: 230–234.CrossRefGoogle Scholar
  2. 2.
    Ghigo E, Bellone J, Aimaretti G, et al, 1996 Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children. J Clinical Endocrinol Metab 81: 3323–3327.Google Scholar
  3. 3.
    Mazzola A, Meazza C, Travaglino P, et al, 2008 Unreliability of classic provocative tests for the diagnosis of growth hormone deficiency. J Endocrinol Invest 31: 159–162.CrossRefPubMedGoogle Scholar
  4. 4.
    Maghnie M, Valtorta A, Moretta A, et al, 1993 Diagnosis of growth hormone deficiency: the value of short term hypocaloric diet. J Clinical Endocrinol Metab 77: 1372–1378.Google Scholar
  5. 5.
    Mauras N, Walton P, Nicar M, Welch S, Rogol A, 2000 Growth hormone stimulation testing in both short and normal statured children: use of an immunofunctional assay. Pediatr Res 48: 614–618.CrossRefPubMedGoogle Scholar
  6. 6.
    Radetti G, Buzi F, Cassar W, Paganini C, Stacul E, Maghnie M, 2003 Growth hormone secretory pattern and response to treatment in children with short stature followed to adult height. Clin Endocrinol (Oxf) 59: 27–33.CrossRefGoogle Scholar
  7. 7.
    Cianfarani S, Tondinelli T, Spadoni GL, Scirè G, Boemi S, Boscherini B, 2002 Height velocity and IGF-I assessment in the diagnosis of childhood onset GH insufficiency: do we still need a second GH stimulation test? Clin Endocrinol (Oxf) 57: 161–167.CrossRefGoogle Scholar
  8. 8.
    Meazza C, Gertosio C, Pagani S, et al, 2016 Is retesting in growth hormone deficient children really useful? Minerva Endocrinol Jun 15.Google Scholar
  9. 9.
    Radetti G, Wu Z, Elsedfy HH, El Kholy M, Bozzola M, Strasburger CJ, 2008 Pegvisomant-primed GH stimulation test. Clin Endocrinol (Oxf) 68: 951–956.CrossRefGoogle Scholar
  10. 10.
    Colao A, Pivonello R, Auriemma RS, et al, 2006 Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154: 467–477.CrossRefPubMedGoogle Scholar
  11. 11.
    Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z, Strasburger CJ, 2002 Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J Clinical Endocrinol Metab 87: 5737–5745.CrossRefGoogle Scholar
  12. 12.
    Thorner MO, Strasburger CJ, Wu Z, et al, 1999 Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clinical Endocrinol Metab 84: 2098–2103.Google Scholar
  13. 13.
    Tanner JM, Whitehouse RH, 1976 Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 51: 170–179.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Cole TJ, Freeman JV, Preece MA, 1998 British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 17: 407–429.CrossRefPubMedGoogle Scholar
  15. 15.
    Greulich WW, Pyle SL 1969 Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford University Press, Stanford, USA.Google Scholar
  16. 16.
    GH Research Society, 2000 Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH research society. J Clin Endocrinol Metab 85: 3990–3993.Google Scholar
  17. 17.
    Yuen KC, Frystyk J, Rhoads SA, Bidlingmaier M, 2016 Pegvisomant-primed glucagon stimulation test in assessing GH reserve and GH/IGF kinetics in adults suspected of GH deficiency. Pituitary 19: 65–74.CrossRefPubMedGoogle Scholar
  18. 18.
    Thissen JP, Ketelslegers JM, Underwood LE, 1994 Nutritional regulation of the insulin-like growth factors. Endocr Rev 15: 80–101.PubMedGoogle Scholar
  19. 19.
    Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH; Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society, 2016 Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr 86: 361–397.CrossRefPubMedGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2017

Authors and Affiliations

  • Giorgio Radetti
    • 1
  • Heba H. Elsedfy
    • 2
  • Randa Khalaf
    • 2
  • Cristina Meazza
    • 3
  • Sara Pagani
    • 3
  • Mohamed El Kholy
    • 2
  • Riccardo Albertini
    • 4
  • Anna Maria De Stefano
    • 5
  • Antonella Navarra
    • 5
  • Annalisa De Silvestri
    • 6
  • Mauro Bozzola
    • 3
  1. 1.MarienklinikBolzanoItaly
  2. 2.Department of PaediatricsAin Shams UniversityCairoEgypt
  3. 3.Dipartimento di Medicina Interna e Terapia Medica, Unità di Pediatria ed AdolescentologiaUniversità degli Studi di Pavia, Fondazione IRCCS Policlinico San MatteoPaviaItaly
  4. 4.Laboratory of Clinical Chemistry Fondazione IRCCS Policlinico San MatteoPaviaItaly
  5. 5.IRCCS Fondazione Salvatore MaugeriPaviaItaly
  6. 6.Biometry and Clinical Epidemiology, Scientific DirectionFondazione IRCCS Policlinico San MatteoPaviaItaly

Personalised recommendations